;or a salt thereof. Also, the group of inventions includes use of said compound or its salt as inhibitor of mutant FLT3; method for predicting a therapeutic effect by administering said pharmaceutical composition to a subject which includes a step for detecting the presence or absence of a FLT3 mutation; method of selecting a subject, using said pharmaceutical composition, which includes a step for detecting presence or absence of mutation FLT3; and method of determining, whether or not said pharmaceutical composition is administered to a subject which includes a step for detecting the presence or absence of a FLT3 mutation.;EFFECT: group of inventions provides application of compounds and compositions possessing mutant FLT3 inhibition, in particular, with mutation TDK.;23 cl, 1 dwg, 5 tbl, 3 ex"/> PHARMACEUTICAL COMPOSITION FOR TREATING A MALIGNANT TUMOR, FLT3-POSITIVE, A FLT3 MUTANT INHIBITOR AND USE THEREOF
首页> 外国专利> PHARMACEUTICAL COMPOSITION FOR TREATING A MALIGNANT TUMOR, FLT3-POSITIVE, A FLT3 MUTANT INHIBITOR AND USE THEREOF

PHARMACEUTICAL COMPOSITION FOR TREATING A MALIGNANT TUMOR, FLT3-POSITIVE, A FLT3 MUTANT INHIBITOR AND USE THEREOF

机译:用于治疗恶性肿瘤,FLT3阳性,FLT3突变抑制剂的药物组合物及其用途

摘要

FIELD: pharmaceuticals; medicine.;SUBSTANCE: first invention represents use of a pharmaceutical composition for treating a malignant tumor, mutation FLT3 positive, wherein the FLT3 mutation includes a TDK mutation containing a compound of general formula [1]; ;or a salt thereof. Also, the group of inventions includes use of said compound or its salt as inhibitor of mutant FLT3; method for predicting a therapeutic effect by administering said pharmaceutical composition to a subject which includes a step for detecting the presence or absence of a FLT3 mutation; method of selecting a subject, using said pharmaceutical composition, which includes a step for detecting presence or absence of mutation FLT3; and method of determining, whether or not said pharmaceutical composition is administered to a subject which includes a step for detecting the presence or absence of a FLT3 mutation.;EFFECT: group of inventions provides application of compounds and compositions possessing mutant FLT3 inhibition, in particular, with mutation TDK.;23 cl, 1 dwg, 5 tbl, 3 ex
机译:领域:制药;发明的目的:第一项发明代表药物组合物用于治疗恶性肿瘤,FLT3阳性突变的用途,其中所述FLT3突变包括含有通式[1]化合物的TDK突变。 ;或其盐。同样,发明组包括所述化合物或其盐作为突变体FLT3的抑制剂的用途;和通过将所述药物组合物施用于受试者来预测治疗效果的方法,该方法包括检测FLT3突变存在与否的步骤;使用所述药物组合物选择受试者的方法,其包括检测突变FLT3存在与否的步骤;本发明提供了具有突变FLT3抑制作用的化合物和组合物的应用,以及确定所述药物组合物是否施用于受试者的方法,所述方法包括用于检测FLT3突变的存在或不存在的步骤。 ,带有TDK突变。; 23 cl,1 dwg,5 tbl,3 ex

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号